MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1080/17474086.2016.1216311

Медицинская библиотека · Expert review of hematology · 2016

The role of proteasome inhibition in the treatment of malignant and non-malignant hematologic disorders.

Citrin Rebecca, Foster Jessica B, Teachey David T

СтатьяОбзорПеревод пока не подготовлен

Аннотация

INTRODUCTION

Proteasome inhibitors have garnered interest as novel chemotherapeutic agents based on their ability to inhibit the growth of cancer cells by altering the balance of intracellular proteins. Initial clinical trials of this drug class focused on bortezomib, a reversible inhibitor of the 20S proteasome, with promising results for the treatment of adult hematologic malignancies, including multiple myeloma and non-Hodgkin lymphoma.

AREAS COVERED: This article will review the use of bortezomib and other proteasome inhibitors in both adult and pediatric populations, with a focus on their use in pediatrics. Expert commentary: Bortezomib moved into the pediatric oncology arena with encouraging results in multiple early phase trials for relapsed acute lymphoblastic leukemia and acute myeloid leukemia. Bortezomib is also being studied in the treatment of non-malignant disorders, including antibody-mediated allograft rejection, graft-versus-host disease, and autoimmune cytopenias. The numerous applications of bortezomib have inspired the development of second-generation proteasome inhibitors.

Для цитирования: Citrin Rebecca, Foster Jessica B, Teachey David T. The role of proteasome inhibition in the treatment of malignant and non-malignant hematologic disorders.. Expert review of hematology. 2016. DOI: 10.1080/17474086.2016.1216311.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.